Toshinori Oinuma
Papers
1
Total Citations
12
H-Index
1
About
Toshinori Oinuma has made significant contributions to the molecular pathology of breast cancer, particularly in refining the assessment of HER2 status—a critical biomarker for guiding trastuzumab (Herceptin) therapy. His key research areas include oncogene amplification, laser-assisted microdissection techniques, and the correlation between protein expression and mRNA levels in human cancers. In his highly cited 2004 study, Oinuma employed laser-assisted microdissection to precisely compare HER2 mRNA amplification with immunohistochemical protein scoring in breast cancer tissues. This work demonstrated that while immunohistochemistry (score 3+) is a reliable indicator for trastuzumab eligibility, mRNA analysis offers a more quantitative and potentially more accurate assessment of HER2 status, helping to reduce false positives and improve patient stratification. With 12 citations, this study has influenced subsequent research on molecular diagnostics and personalized oncology. Oinuma’s meticulous approach underscores the importance of integrating genomic and proteomic data for precise cancer treatment, making his work a valuable reference for students and researchers exploring biomarker validation and targeted therapy optimization.
Research Focus
Key Achievements
Top Papers
- 1